Skip to main content

Advertisement

SpringerLink
Log in

Impact of Imatinib Adherence on the Cytogenetic Response in Pediatric Chronic Myeloid Leukemia - Chronic Phase

  • Clinical Brief
  • Published:
The Indian Journal of Pediatrics Aims and scope Submit manuscript

Abstract

The authors aimed to study the impact of adherence to imatinib during initial 6 mo on the cytogenetic response in pediatric chronic myeloid leukemia - chronic phase (CML CP). The hospital records of pediatric CML patients (age ≤18 y) from 2009 through 2012, were analyzed retrospectively for the drug adherence and cytogenetic response (CyR) at 6 mo. Forty eight children were analyzed, with the median age of 13 y (range 5–18) and slight male preponderance (M:F- 1.18:1). Sokal scores were low, intermediate and high in 14 (29.3 %), 26 (54.1 %), 8 (16.6 %) children respectively. Only a little more than half of the children were adherent (58 %). At the end of 6 mo, complete cytogenetic response (CCyR) was achieved by 78.5 % of adherent children as compared to 5 % of non-adherent children. Majority (80 %) of the non-adherent children had only a partial cytogenetic response (PCyR). Therefore, it is concluded that most of the adherent children had optimal cytogenetic response at the end of 6 mo and majority of those in the non-adherent group did not attain it.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abbreviations

CML CP:

Chronic myeloid leukemia - chronic phase

CHR:

Complete hematological response

CyR:

Cytogenetic response

PCyR:

Partial cytogenetic response

CCyR:

Complete cytogenetic response

MPR:

Medication possession rate

MEMS:

Micro electronic monitoring system

References

  1. Peng B, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol. 2004;22:935–42.

    Article  CAS  PubMed  Google Scholar 

  2. Bazeos A, Khorashad J, Mahon F-X, et al. Long term adherence to imatinib therapy is the critical factor for achieving molecular responses in chronic myeloid leukemia patients; American Society of Hematology (ASH) 51st annual meeting: Abstract. New Orleans, LA; 2009.

  3. Pemmaraju N, Cortes J. Chronic myeloid leukemia in adolescents and young adults: patient characteristics, outcomes and review of the literature. Acta Haematol. 2014;132:298–306.

    Article  CAS  PubMed  Google Scholar 

  4. Baccarani M, Deininger MW, Rosti G, et al. European leukemia net recommendations for the management of chronic myeloid leukemia. Blood. 2013;122:872–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–97.

    Article  CAS  PubMed  Google Scholar 

  6. Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28:2381–8.

    Article  CAS  PubMed  Google Scholar 

  7. Darkow T, Henk HJ, Thomas SK, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics. 2007;25:481–96.

    Article  CAS  PubMed  Google Scholar 

  8. Ibrahim AR, Eliasson L, Apperley JF, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood. 2011;117:3733–6.

    Article  CAS  PubMed  Google Scholar 

  9. Noens L, van Lierde MA, De Bock R, Verhoef G, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113:5401–11.

    Article  CAS  PubMed  Google Scholar 

  10. Ganesan P, Sagar TG, Dubashi B, et al. Nonadherence to Imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol. 2011;86:471–4.

    Article  PubMed  Google Scholar 

  11. dos Reis SRC, de Souza Quixadá AT, Nunes ST, et al. Adherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital. Rev Bras Hematol Hemoter. 2013;35:174–9.

    PubMed  PubMed Central  Google Scholar 

  12. Jabbour E, Kantarjian H, O’Brien S, et al. The achievement of an early complete cytogenetic response ismajor determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood. 2011;118:4541–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

Max foundation, Novartis Oncology Access for free supply of Imatinib Mesylate (Glivec) in India.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Nizams Institute of Medical Sciences, Hyderabad, Telangana, 500082, India

    Ranga Raman Ganta, Srividya Nasaka & Sadashivudu Gundeti

Authors
  1. Ranga Raman Ganta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Srividya Nasaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sadashivudu Gundeti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sadashivudu Gundeti.

Ethics declarations

Contributions

All the authors collected the hospital records of CML children and analyzed their data. Prof. Lakshmi Srinivas Maddali, Head, Department of Medical Oncology, Nizams Institute of Medical Sciences, Hyderabad, will act as guarantor for the paper.

Conflict of Interest

None.

Source of Funding

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ganta, R.R., Nasaka, S. & Gundeti, S. Impact of Imatinib Adherence on the Cytogenetic Response in Pediatric Chronic Myeloid Leukemia - Chronic Phase. Indian J Pediatr 83, 1009–1012 (2016). https://doi.org/10.1007/s12098-015-2007-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12098-015-2007-9

Keywords

Search

Navigation